First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Nguyen KS, Neal JW

Biologics: Targets and Therapy 2012, 6:337-345

Published Date: 25 September 2012